Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Global Forecast 2024-2030
The Anti-Obesity Therapeutics Market size was estimated at USD 9.98 billion in 2023 and expected to reach USD 10.81 billion in 2024, at a CAGR 8.44% to reach USD 17.60 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Anti-Obesity Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Obesity Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.
Market Segmentation & Coverage
This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Treatment Type
Medications
Bupropion-naltrexone
Adjustable Gastric Banding
Ambulatory Surgical Centers
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Anti-Obesity Therapeutics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Obesity Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Anti-Obesity Therapeutics Market?
- What is the market share of the leading vendors in the Anti-Obesity Therapeutics Market?
- Which modes and strategic moves are suitable for entering the Anti-Obesity Therapeutics Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Anti-Obesity Therapeutics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing incidences of obesity and related disorder
- 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
- 5.1.1.3. Introduction of novel anti-obesity drugs
- 5.1.2. Restraints
- 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing clinical trials and research & development activities
- 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
- 5.1.4. Challenges
- 5.1.4.1. Limited of knowledge regarding weight management
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Anti-Obesity Therapeutics Market, by Treatment Type
- 6.1. Introduction
- 6.2. Medications
- 6.3.1. Bupropion-naltrexone
- 6.3.2. Liraglutide
- 6.3.3. Orlistat
- 6.3.4. Phentermine-topiramate
- 6.3.5. Semaglutide
- 6.3. Treatments
- 6.4.1. Adjustable Gastric Banding
- 6.4.2. Endoscopic Sleeve Gastroplasty
- 6.4.3. Gastric Bypass Surgery
- 7. Anti-Obesity Therapeutics Market, by End-use
- 7.1. Introduction
- 7.2. Ambulatory Surgical Centers
- 7.3. Hospitals
- 7.4. Specialty Clinics
- 8. Americas Anti-Obesity Therapeutics Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Anti-Obesity Therapeutics Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Boehringer Ingelheim International GmbH
- 12.1.2. Bristol-Myers Squibb Company
- 12.1.3. Currax Pharmaceuticals LLC
- 12.1.4. Eisai Co., Ltd.
- 12.1.5. Eli Lilly and Company
- 12.1.6. F. Hoffmann-La Roche Ltd.
- 12.1.7. GlaxoSmithKline PLC
- 12.1.8. Merck & Co., Inc.
- 12.1.9. Norgine B.V.
- 12.1.10. Novartis AG
- 12.1.11. Novo Nordisk A/S
- 12.1.12. Pfizer Inc.
- 12.1.13. Rhythm Pharmaceuticals, Inc.
- 12.1.14. SHIONOGI & Co., Ltd.
- 12.1.15. Takeda Pharmaceutical Company Limited
- 12.1.16. Vivus LLC
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
- FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
- FIGURE 7. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
- FIGURE 8. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
- FIGURE 10. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook